Bell Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bell Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76K	Hold	6	–	–	﹤0.01%	1375
2026 Q1	$1.67K	Hold	6	–	–	﹤0.01%	1381
2025 Q4	$1.82K	Sell	6 -1	-14%	-$312	﹤0.01%	1379
2025 Q3	$1.96K	Hold	7	–	–	﹤0.01%	1339
2025 Q2	$1.69K	Buy	7 +6	+600%	+$1.42K	﹤0.01%	1413
2025 Q1	$244	Sell	1 -2	-67%	-$602	﹤0.01%	1859
2024 Q4	$986	Hold	3	–	–	﹤0.01%	1590
2024 Q3	$1K	Hold	3	–	–	﹤0.01%	1589
2024 Q2	$820	Sell	3 -2	-40%	-$582	﹤0.01%	1661
2024 Q1	$1.73K	Buy	5 +2	+67%	+$658	﹤0.01%	1418
2023 Q4	$969	Sell	3 -9	-75%	-$2.82K	﹤0.01%	1607
2023 Q3	$4.3K	Sell	12 -1	-8%	-$386	﹤0.01%	885
2023 Q2	$4.93K	Sell	13 -7	-35%	-$2.85K	﹤0.01%	834
2023 Q1	$9.58K	Buy	20 +2	+11%	+$936	﹤0.01%	497
2022 Q4	$7.57K	Buy	18 +3	+20%	+$1.21K	﹤0.01%	598
2022 Q3	$6K	Buy	15 +2	+15%	+$997	﹤0.01%	572
2022 Q2	$6K	Buy	+13	New	+$6.77K	﹤0.01%	597
2021 Q4	$10K	Buy	13 +1	+8%	+$748	﹤0.01%	479
2021 Q3	$9K	Buy	+12	New	+$8.99K	﹤0.01%	471

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bell Investment Advisors's BIO Position: Q2 2026 in Review

Bell Investment Advisors held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 6 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Bell Investment Advisors first reported a position in BIO in Q3 2021 and has held it in 19 quarters since. The position peaked at $10K in Q4 2021. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Bell Investment Advisors held 6 shares of Bio-Rad Laboratories Class A worth $1.76K as of Q2 2026.
Bell Investment Advisors left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1375 holding.
Bell Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2021 and has held it in 19 quarters since.
Bell Investment Advisors's Bio-Rad Laboratories Class A position peaked at $10K in Q4 2021.
400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.